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SAMMANFATTNING 
Osteoartrit (OA) är ett stort problem hos hästar då det orsakar upp till 60% av alla hältor. OA 
är en inflammatorisk och progressiv sjukdom som uppkommer när ledens naturliga balans 
mellan anabola och katabola processer rubbas och jämnvikten förskjuts så att de katabola 
processerna tar över. Behandlas inte OA i tid kommer denna obalans att fortgå och efter en tid 
kommer degenerativa, kroniska skador på ledbrosket att uppstå. När sjukdomen har gått så långt 
är det svårt att behandla med lyckat resultat. Lyckas man upptäcka sjukdomen i ett tidigt 
stadium och sätter in behandling direkt är prognosen bättre. 
Idag är intraartikulär injektion av kortikosteroider ett vanligt sätt att behandla OA. Trots att 
kortikosteroider är effektiva när det gäller att ta bort kliniska symptom så som hälta är denna 
behandlingsmetod något kontroversiell och omdiskuterad. Anledningen till detta är att vissa 
hävdar att kortikosteroider har negativa effekter på ledbrosket.  
Inom veterinärmedicin är det framförallt tre olika kortikosteroider som är populära för 
intraartikulär behandling i samband med OA hos häst, betamethason, triamcinolon acetonid 
(TA) och methylprednisolon acetat (MPA). Syftet med denna uppsats är att jämföra dessa tre 
farmakologiska formuleringar för att utvärdera om det finns några uppenbara skillnader mellan 
dem, speciellt i avseende på hur ledbroskets matrix molekyler påverkas och hur effektiva de är 
på att reducera hälta. 
Det är svårt att utifrån de studier som idag finns tillgängliga att dra någon konkret slutsats om 
vilket av de tre kortisonpreparat som är det bästa alternativet för behandling av OA. 
Anledningen till detta är att studierna som är gjorda är utformade på olika sätt och det är därför 
svårt att jämföra dem med varandra. Det som kan konstateras är dock att det inte finns några 
uppenbara tecken på att intraartikulär behandling med TA eller betamethason leder till skador 
på ledbrosket så länge man använder korrekta doser och låter hästen vila under den tid som 
kortisonet verkar. MPA är mer tveksamt, här har många studier visat på negativa effekter hos 
ledbrosket. Dock har man i dessa studier använt friska hästar, höga doser och lederna har 
injicerats med täta intervall. Det skulle vara intressant att se om man kunde se samma negativa 
effekter på ledbrosket även vid lägre doser och mindre frekventa injektioner av MPA. 
Sammanfattningsvis kan det konstateras att studier där dessa tre typer av kortikosteroider 
jämförs på likvärdigt sätt krävs för att kunna dra bättre slutsatser om vilket typ som fungerar 
bäst.  
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SUMMARY 
Osteoarthritis is a huge problem in equine veterinary medicine since it causes up to 60% of all 
lameness. OA is an inflammatory and progressive disease, which occur when the natural 
balance between anabolic and catabolic processes is disturbed. If this imbalance continues and 
no treatment is insert, degenerative and chronic damage on the articular cartilage will occur. 
When the disease comes to this irreversible stage it is difficult to achieve a successful treatment 
but in an early stage of the disease treatment may improve the prognosis.  
Today intra-articular injections with corticosteroids is a common treatment of OA. 
Corticosteroids are effective to reduce lameness but the treatment is controversial and heavily 
discussed. The reason for this is that some people believe that corticosteroids affect the articular 
cartilage metabolism negatively.  
In equine veterinary medicine, mainly three types of corticosteroids are used, betamethasone, 
triamcinolone acetonide (TA) and methylprednisolone acetate (MPA). The purpose of this study 
is to investigate if there are any differences between these three pharmaceutical preparations, 
with focus on the effect on articular cartilage matrix molecules and how effective their therapy 
reduces lameness.  
Since studies within the subject are designed in different ways it is difficult to compare them in 
a fair way. Therefore, it is impossible to determine which of the three corticosteroids that works 
in the most favorable way in reducing OA. What can be said is that there is no significant 
evidence that TA or betamethasone would be harmful to the articular cartilage as long as the 
dosage is correct and the horse rest while the drug is acting. MPA is a bit more doubtful. Studies 
have shown that MPA affect the articular cartilage in a negative way, but the methods in these 
studies can be questioned since the horses are injected with high doses and frequent intervals. 
Studies with more relevant doses and injection intervals would be wishful. As a conclusion, 
more studies which compare these three types of corticosteroids are necessary to be able to say 
which is the best alternative as treatment of OA in horses.  
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INTRODUCTION 
Osteoarthritis (OA) is a huge problem in equine veterinary medicine since it causes up to 60% 
of all lameness (McIlwraith et al., 2012). In a healthy joint there is a balance between catabolic 
and anabolic processes and when this balance is disrupted OA can evolve (Frisbie, 2005). OA 
is a low-grade inflammatory and progressive joint disease that include all structures in the 
synovial joint such as joint capsule, synovial fluid, articular cartilage, subchondral bone, 
tendons and ligaments. Damage to any of these structures leads to biochemical imbalance and 
with time, degradation of articular cartilage will occur (Heinegård et al 2011).  
Today there are no available methods for diagnosing OA at an early stage of the disease. In 
order to determine OA the horses must show clinical signs such as lameness or swelling of the 
joint. In this stage the inflammation is well developed and potent anti-inflammatory drugs are 
required to take the horse back to training. Corticosteroids are a common way to treat horses 
diagnosed with OA(Frisbie, 2005). Corticosteroids relieve the symptoms of the disease but it is 
well discussed how these drugs negatively affects the articular cartilage (McIlwraith et al., 
2012). In equine sports medicine mainly three types of corticosteroids are used for intra-
articular treatment of OA. These are betamethasone, triamcinolone acetonide, betamethasone 
esters and methylprednisolone acetate (McIlwraith et al., 2012). 
This essay will describe the anatomy and physiology of the synovial joint, the pathogenesis of 
OA and then discuss benefits compared with the side effects of corticosteroids as treatment of 
OA. Is there a difference between short-acting and long-acting corticosteroids with respect to 
positive clinical effect and negative side effects on the articular cartilage?   
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MATERIAL AND METHODS  
This study is based on scientific papers, studies and publications relevant to the topic. The 
following web site was used for finding materials: 
http://www.pubmed.com 
The phrases used for search were “corticosteroids”,” articular cartilage”,” triamcinolone 
acetonide”,” betamethasone esters”,” methylprednisolone acetate”. 
These phrases were combined with “equine AND + OR horse”.  
Basic anatomy, physiology and pathology about synovial joints is taken from the book Joint 
Disease in the Horse.  
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LITTERATURE REVIEW 
Synovial joint – anatomy and physiology 
The synovial joint has two major functions, enable movement and transfer load. To enable these 
functions the joint consists of several structural components such as hyaline cartilage, 
subchondral bone, joint capsule with synovial fluid, tendons and ligaments. The synovial joint 
is defined as an organ where all structures interact with each other to promote optimal function 
of joint movement (McIlwraith et al., 2015). 
 
 
Figure 1.  General anatomy of a synovial joint (Gessbo 2004) 
Joint capsule  
The capsule is comprised of two layer, the outer fibrous layer, called stratum fibrosum and the 
inner layer, called the synovial membrane. The fibrinous layer is interacting with extra-articular 
structures such as ligaments and tendons and is important for the stabilization of the joint. The 
inner synovial membrane can be further divided into two layers, the inner synoviocytes layer 
(intima synovialis) and the subsynovial layer (stratum subsynoviale). Two types of 
synoviocytes are present in the intima synovialis, these are type-A and type-B synoviocytes. 
Type-A are responsible for phagocytosis whereas type-B produce and secrete proteins 
(McIlwraith et al., 2015). 
Synovial fluid 
The synovial fluid is an ultra-filtrate of blood plasma but it also contains components produced 
by the synovial membrane lining cells, for example hyaluronan (HA) and lubricin (Köning et 
al 2009). HA gives the synovial fluid its viscosity. The viscous nature of the synovial fluid 
allows it to support transient shear stresses and to absorb some of the energy generated by 
movement. The levels of HA are reduced in synovial fluid during development of OA (Sofat, 
2009). Also reduced chain length of HA can be seen in injured joints (Brown et al., 2007). The 
1. Joint	cavity	
2. Joint	capsule	
3. Articular	cartilage		
4. Synovial	fluid	
5. Subchondral	bone	
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glycoprotein lubricin and hyaluronan together acts synergistically to lubricate the surface and 
articular cartilage (Bonnevie et al., 2016). Lubricin adheres to the surface of the articular 
cartilage and synovial membrane and reduce the surface tension and forcing opposing articular 
surfaces apart to prevent fusion (McIlwraith et al., 2015).  
Articular cartilage 
Articular cartilage is a highly specialized connective tissue that covers the surface of the 
subchondral bone (McIlwraith et al., 2015). It is avascular and rich in extracellular matrix, 
which consists of collagen, proteoglycans, non-collagenous proteins and water (Van Weeren et 
al., 2016).  
Chondrocytes 
Chondrocytes are the only type of cells in adult cartilage and the cell density is low. The 
chondrocytes are responsible for synthesis and organization of the extracellular matrix. Based 
on the organization of the chondrocytes, the articular cartilage can be divided into four zones. 
Zone I-III are the unmineralized zones and these are delineated from zone IV which is the 
calcified cartilage by the tidemark. Tidemark is the junction between calcified and non-calcified 
cartilage. In zone I (superficial zone) the chondrocytes are relatively small and elongated and 
this zone has the highest cell density. Zone II (transitional zone) has larger and rounded cells 
and in zone III the chondrocytes are even larger and arranged in vertical columns (McIlwraith 
et al., 2015). 
 
Figure 2. Immunohistochemistry section of Tolouidine blue stained equine articular cartilage 
from the third carpal bone of a four-year-old trotter (Skiöldebrand 2004) 
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Extracellular matrix 
Extracellular matrix consists of collagen, proteoglycans, non-collagenous proteins, water and 
lipids. Most of the collagen (85-90%) is type II collagen. Type II collagen tensile strength to 
the cartilage and it has a higher hydroxylation of lysin and more glycosylation than other types 
of collagen. Type II collagen fibrils consists of three α chains that are wound around each other 
to form a triple helix. By cross-linking to each other the collagen fibrils form a three-
dimensional meshwork. The inter fractions in collagen have a long half-life (t1/2 = 300 days) 
(Vandeweerd et al., 2015). In the collagen framework proteoglycans are enmeshed. 
Proteoglycan consists of a protein core which one or more glucosaminoglycans are bound 
covalently to. Unlike collagen proteoglycans have a short half-life (t/2 = 8 to 10 days) 
(Vandeweerd et al., 2015). The most common proteoglycan in adult cartilage is aggrecan. To 
the central protein core of aggrecan a large number of glucosaminoglycans, especially 
chondroitin sulphate, but also keratin sulphate are covalently attached (Platt et al., 1998). 
Aggrecan also has three globular domain, G1, G2 and G3. G1 and G2 are placed at the N-
terminal, which is the hyaluronan binding region. G3 is found at the C-terminal in the other end 
of the molecule. Between G2 and G3 most of the glucosaminoglycans are found. 
Glucosaminoglycans are negatively charged and therefore attracts water, which contributes to 
the elasticity of the cartilage. Loss of glucosaminoglycans therefore makes the cartilage less 
elastic and more sensitive for pressure. Another important molecule in extracellular matrix is 
Cartilage oligomeric matrix protein (COMP), which is a pentameric, non-collagenous 
glycoprotein. COMP binds to collagen I, II and IX. These bonds are essential for the three 
dimensional structure of the collagen network (Skiöldebrand, 2010).  
Subchondral bone 
The subchondral bone provides structural support to the overlying cartilage. The metabolism in 
the bone is high and it is well vascularized and innervated by nerves. The bone adapts to the 
load it is exposed to and during repeated high load thickness and subchondral bone sclerosis 
can be detected at the X-ray. Bone is composed of an inorganic component of mineral salts and 
an organic component of mainly type I collagen, proteoglycan, glucosaminoglycans and water. 
The inorganic phase gives the bone its hardness and rigidity whereas the organic phase provides 
flexibility and resiliency (McIlwraith et al., 2015).  
Tendons and ligament  
Tendons and ligament are soft tissue which together with muscles support the joint 
mechanically and act cushioning. The ligaments can be extra-articular, called collateral 
ligaments or intra-articular (McIlwraith et al., 2015). 
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Osteoarthritis  
Osteoarthritis (OA) is a chronic, debilitating, low-grade inflammatory joint disease and one of 
the most common causes of lameness in horses. The risk factors for development of OA has 
been classified into two main groups, abnormal loading on normal cartilage (1) or normal 
loading on abnormal cartilage (2) (McIlwraith et al., 2012).  
In a healthy joint an equilibrium between anabolic and catabolic factors exists. During 
development of OA this balance is disturbed and the catabolic processes takes over the anabolic 
(Mueller et al., 2011). OA can be initiated in different parts of the synovial joint, for example 
in  synovial membrane. This is called a synovitis and initiates release of proinflammatory 
cytokines like IL-1β and TNF-α. Increased levels of IL-1β and TNF- α creates a cascade 
reaction leading to increased level of matrix-degrading enzymes such as matrix 
metalloproteinase (MMP), aggrecanases and prostaglandins. Also a reduction of extracellular 
matrix protein synthesis can be seen. It is not possible to diagnose OA at an early stage and 
when these catabolic processes continues it will end up with destruction and loss of articular 
cartilage. Early changes in articular cartilage are characterized by loss of proteoglycans and 
changes in the organization of collagen in the superficial zone. (Saarakkala et al., 2010) When 
degradation continues and the disease progress to a later stage also a loss of collagen can be 
seen (Huenbner et al., 2009). 
Interleukin-1β (IL-1β) 
IL-1β is a pro-inflammatory cytokine which is important in the early development of OA. 
Increased levels of IL-1 β is found in synovial fluid in joints in which development of OA 
occurs. IL- 1β binds to IL-1 receptors on the cell membrane and activate matrix 
metalloproteinases, aggrecanase and prostaglandin E2. There is also an increased number of 
IL- 1 receptors in osteoarthritic cartilage which also leads to increased sensitivity of IL- 1β 
(Mueller et al., 2011).  
Tumor necrosis factor -α (TNF- α)  
TNF- α is also a pro-inflammatory cytokine which acts synergistically with IL- 1β. It stimulates 
expression of matrix-degrading enzymes and reduces synthesis of extracellular matrix. Like IL- 
1β, TNF- α inhibit chondrocytes to synthesis proteoglycans and collagen. (Mueller et al., 2011). 
Matrix metalloproteinase (MMP)  
MMPs are zinc-dependent enzymes, synthesized by chondrocytes involved in extracellular 
matrix degradation. During development of OA when the levels of IL-1β and TNF- α increase, 
these molecules binds to their respective cell receptor in chondrocytes and signaling pathways 
that result in upregulation of MMP. MMP-13 has proven to be especially important since it both 
can cleave collagen type II and proteoglycans in articular cartilage. It has been seen that levels 
of MMP-13 increase when chondrocytes are exposed to mechanical stress (Kawaguchi 2008). 
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Aggrecanases  
Aggrecanases are extracellular proteases and belongs to a family called the ADAMTS. When 
talking about OA ADAMTS-4 and ADAMTS-5 are especially important (Abramson et al., 
2009). Increased levels of IL- 1β and TNF- α leads to increased expression of aggrecanases and 
this results in loss of aggrecan in the cartilage (Mueller et al., 2011).  
Prostaglandin E2 (PGE2) 
PGE2 is an important inflammatory mediator and the production requires two enzymes, 
prostaglandin E synthase and cyclooxygenase 2 (COX-2). These enzymes are both induced by 
IL-1β and because of this PGE2 levels increase as a result of higher concentration of IL- 1β 
(Mueller et al., 2011). PGE2 inhibit synthesis of proteoglycans and increase the levels of 
ADAMTS-5 and MMP-13 which leads to degradation of aggrecan and collagen II (Attur et al., 
2008). 
Nitric oxide (NO) 
NO is produced by osteoarthritic chondrocytes and drives the catabolic process in the joint and 
is involved in the development of OA in many ways.  IL- 1β stimulates overexpression of 
inducible nitric oxide synthase (iNOS) which leads to high levels of NO. NO has the properties 
to inhibit synthesis of proteoglycan and collagen in chondrocytes and also induce chondrocyte 
apoptosis (Mueller et al 2011).  
CORTICOSTEROIDS 
The optimal treatment of OA would be an agent that both relieve the symptoms of lameness 
(symptom-modifying OA drug, SMOAD) and produce disease modifying effects, (disease-
modifying OA drug, DMOAD) by inhibit the progression (McIlwraith et al., 2012). 
Corticosteroids are potent anti-inflammatory drugs and in that way helpful in reliving symptoms 
of OA but it has also been shown that corticosteroids negatively affect the cartilage, for example 
it decreases collagen type II synthesis and proteoglycan content (Todhunter et al., 1998). Intra-
articular injections of corticosteroids are therefore controversial and benefits compared with the 
side effects are heavily debated.  
In equine veterinary medicine three corticosteroids are mainly used as treatment of OA, these 
are betamethasone, triamcinolone acetonide (TA) and methylprednisolone acetate (MPA) 
(McIlwraith et al., 2012). Below these three pharmaceutical preparations will be compared to 
each other, especially with respect to differences in affecting the articular cartilage matrix 
molecules after intra-articular injections.  
Betamethasone  
Betamethasone is considered as the most short-acting corticosteroid in this paper. Usually 
betamethasone, compared from TA and MPA is injected intra-articular as a mixture of two type 
of esters. One water soluble called betamethasone sodium phosphate and one called 
betamethasone acetate which has a depot effect and a slow release (Bertone et al., 2004). In a 
study by Knych et al (2017) it was shown that the concentration of betamethasone in synovial 
fluid was immeasurable in synovial fluid between 14 and 21 days after intra-articular injection.  
 10 
 
 
In an in vivo study 12 horse received arthroscopically created osteochondral fragments on the 
distal radio carpal bone in both front legs. Two weeks after surgery all horses were intra-
articular injected with betamethasone in one of the affected joints and the contralateral joint 
was injected with similar volume of saline. The treatment was repeated on day 35. The horses 
also were divided in to two groups. One group with six horses started an exercise program on 
a high-speed treadmill 17 days after surgery while the remaining horses were kept in box stables 
throughout the hole study. Day 56 post-surgery all horses underwent clinical examination and 
radiographically examinations before they were euthanatized. After euthanasia cartilage 
samples were collected for histological, histochemical and biochemical analysis. In the group 
of horses which had undergone the exercise program five of the six horses shown mild 
lameness. Four of the lame horses were lame in the control limb and the last one was lame in 
the treated limb. In the group with resting horses only five of the six horses could be evaluated 
since the last one got a septic arthritis and was therefore removed from the study. Of these five 
horses two were lame in the treated limb, two in the control limb and one in both the treated 
and the control limb. Neither in the exercised or in the resting group no significant histological 
difference was shown between cartilage from joints injected with betamethasone compared 
with joints injected with saline. In the group with exercised horses the histological changes 
were minimal worse in cartilage from treated joint compared with control joints but there was 
less reduction in safranin O staining in treated joints compared with control joints. The authors 
conclusions by this study was that no consistently severe detrimental effects associated with 
intra-articular injections with betamethasone in therapeutic dose (Foland et al., 1994).  Another 
study has on the other hand shown that betamethasone significantly decrease the synthesis of 
proteoglycans in articular cartilage unless only a low dose is used (Frean et al., 2002).  
Triamcinolone acetonide (TA) 
TA also belongs to the group of short-acting corticosteroids, but it has a longer duration 
compared to betamethasone. It has been shown that TA is absorbed from synovial fluid rapidly 
after injection and 4 days after injection the concentration had significantly decreased. 15 days 
after injection the concentration of TA is undetectable in synovial fluid (Bertone et al., 2004). 
TA seems to have a notable individual variation (Chen et al., 1992).  
Several in vivo studies have demonstrated the ability of TA to reduce lameness in horses with 
surgically induced damage in joint (Frisbie et al., 1997; Kawcak et al., 1998).  According to the 
study by Frisbie et al., 1997, TA except from reduce lameness also increased the concentration 
of HA and glycosaminoglycan in synovial fluid and decreased total protein and less 
inflammatory cell infiltration could be seen. These changes were not only detected in the treated 
joint, even in the control joint these positive effects could be seen (Frisbie et al., 1997). 
Histomorphological parameters in articular cartilage also seems to be better after treatment with 
TA (Frisbie et al., 1997; Kawcak et al., 1998). In in vivo studies, it was shown based on 
histological examinations of cartilage samples treated with TA that TA can protect chondrocytes 
from the toxic effects caused by LPS (Bolt et al., 2008). The same study also indicates that 
concentration of GAG content in cartilage was not affected after treatment with TA. The number 
of empty lacunae and pyknotic nuclei decreased after treatment with TA and stayed at decreased 
levels when the cartilage was exposed for LPS.  If the number of empty lacunae first was 
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increased by treating the samples with LPS, TA could not reduce these negative effects (Bolt et 
al., 2008).   
In another in vivo study, it was shown that healthy joints, intra-articular injected with TA at 
recommended doses had an altered metabolism of articular cartilage already after one injection. 
Increased degradation of collagen type II and aggrecan could be seen but it was reversible and 
when it went back to normal again the degradation was even lower than it was before treatment 
(Céleste et al., 2005).  
Methylprednisolone acetonide (MPA)  
MPA is classified as a long-acting corticosteroid. In Sweden MPA are an uncommon alternative 
as treatment of joints with OA however it is frequently used in other countries, for example in 
the US and in the UK. After intra-articular injections MPA rapidly hydrolyze to the active 
moiety methylprednisolone (MP) (Bertone et al., 2004). How long MP is detectable in synovial 
fluid after injection remains unclear. One study says 10 days (Lillich et al., 1996), another on 
says 39 days (Autefage et al., 1986) and a third on says 77 days (Knych., et al 2014).  
To evaluate the effect of MPA at articular cartilage many studies have been done. A common 
trend in studies is that repeated high doses and repeated injections are used. One example is an 
in vivo study by Chunekamrai et al., (1989) where eight horses without prior signs of lameness 
or OA were injected with 120 mg MPA per joint into the right radiocarpal and intercarpal joint 
once a week for eight weeks. Articular cartilage samples from treated joints indicated a 
decreased intensity of staining in safranin O fast green dye, which represent loss of GAGs in 
extracellular matrix. All samples from injected joints also showed chondrocyte necrosis, hypo 
cellularity and also loss of proteoglycans could be seen. The reduction of synthesis of 
proteoglycans last between 4 and 8 weeks after treatment.  
When it comes to the effect on proteoglycan in articular cartilage after treatment with MPA it 
seems to depends on if  the joint is healthy or not. An in vitro study where cartilage sample 
treated with interleukin-1 to mimic the conditions occurring during development of OA, IL-1 
decreased the synthesis of proteoglycans but if the samples were treated with MPA the synthesis 
of proteoglycan increased (Yates et al., 2006). On the other hand in cartilage samples from 
healthy joint only treated with MPA seems to have a decreased production of proteoglycan 
(Byron et al., 2008). Also a study made for evaluate differences of acting of MPA in healthy 
joints compared to a damaged joints shows that MPA in a healthy joint decreased proteoglycan 
synthesis and the total protein was higher than in control joints. But if the sample first was 
treated with LPS to mimic a joint with OA the negative effects of MPA were not detected 
(Todhunter et al., 1998).   
DISCUSSION 
In all the reviewed studies, there seems to be a general agreement that corticosteroids are 
effective in reducing lameness, which is the reason why it is so frequently used. Unfortunately, 
there is no study that compares betamethasone, triamcinolone acetonide and 
methylprednisolone acetonide to each other. Available studies have different study designs and 
are therefore not fully comparable. 
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Some studies are in vivo and some are in vitro which may give different results. For example, 
cartilage samples in in vitro studies lack the ability to eliminate the drug compared to a joint in 
vivo. A benefit with studies in vitro is on the other hand that it is much easier to get high 
reproducibility among samples which could be hard in in vivo studies since there are individual 
differences between horses. Another difference between studies is if the corticosteroid is 
injected in a healthy joint or a diseased joint with an inflammation already present. If the joint 
is injured there are also diverse ways to induce the damage. Since OA cause an imbalance 
between anabolic and catabolic mediators in the joint it is important to mimic this environment, 
which should be considered when selecting the method to induce the damage. For example, a 
surgically induced fragment may not cause this environment, which is important to remember 
when interpreting result from those studies.  
Based on studies available today it is not possible to define which type of corticosteroid that is 
the best choice for intra-articular injection as treatment of OA, but some trends can be seen.  
Betamethasone has the fewest number of studies and more studies would be desirable. Based 
on available studies betamethasone does not affect the cartilage in any adverse way. One study 
showed reduced synthesis of proteoglycans and GAGs in cartilage after treatment with 
betamethasone (Frean et al., 1994). On the other hand, another study by Foland et al., (1994) 
shows that this negative effect only could be seen in articular cartilage from horses which 
underwent daily training as soon as three days after treatment. This indicate that betamethasone 
does not alter the articular cartilage in an adverse way if the horse is taken out of training while 
the drug is acting. Since betamethasone is a short-acting corticosteroid, the time out of training 
after treatment does not need to be so long and therefore, it is a good alternative for athletic 
horses.  
Triamcinolone acetonide is the only corticosteroid in this essay, which has shown positive 
effect on the cartilage. In the study by Frisbie et al., (1997), it was seen that TA can protect 
chondrocytes from stress and the total protein and the number of inflammatory cells were also 
decreased after treatment with TA (Bolt et al., 2008). On the other hand, some studies insist on 
increased degradation of collagen type II and aggrecan (Céleste et al., 2005). The alteration 
which can be seen after treatment is reversible. When the changes induced by TA returns to 
normal, the degradation of articular cartilage ca be lower than before treatment and therefore, 
TA is a good alternative as treatment of OA. Since TA is capable to protect chondrocytes from 
stress, it is a particularly good choice in an early stage of OA.  
Another interesting fact with TA is that the positive changes which have been seen after 
treatment with TA, such as decreased total protein and decreased number of inflammatory cells 
not only could be seen in the treated joint. The same changes were also seen in the control joint, 
which indicate a systemic spread of the drug (Frisbie et al., 1997).  
The type of corticosteroid which has shown most devastating effects on articular cartilage is 
methylprednisolone acetate. Both reduced staining with safranin O fast green dye which 
indicates loss of GAGs, chondrocyte necrosis, hypo cellularity and loss of proteoglycans have 
been seen after treatment with MPA. These changes were observed as long as 4-8 weeks after 
last injection (Chunekamrai et al., 1989). In the study by a Chunekamrai et al., (1989) high 
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doses and frequent injection . Recommended dosage in Sweden is 40-120 mg per joint and it 
should be enough with one injection (Läkemdelsverket, 2010). In the study by Chunekamrai et 
al., (1989) the maximum dose, 120 mg per joint, is injected weekly for eight weeks. It should 
be interesting to see if the same detrimental effects on the articular cartilage would occur even 
if the horses were injected with a lower dose and only once instead of once a week for eight 
weeks.  
Something interesting with MPA is that it seems like it alters the synthesis of proteoglycans 
different in healthy and non-healthy joints. In healthy joints decreased syntheses of 
proteoglycans have been observed after treatment (Byron et al., 2008). But both if the cartilage 
is stimulated with IL-1 or LPS, treatment can help to increase the reduced synthesis caused by 
IL-1 (Yates et al., 2006) or LPS (Todhunter et al., 1998). This information makes the study by 
Chunekamrai et al., (1989) even more irrelevant since the horses in that study were healthy and 
had no prior signs of lameness or OA.  
MPA should not be the first choice as treatment of OA since it is a long-acting corticosteroid 
and therefore alter the metabolism of the extracellular matrix for a long time after injection. 
Treatment with MPA requires considerably longer time out of training compared to 
betamethasone or TA and therefore it is not the best alternative for athletic horses since this 
horse requires treatment which makes them able to be back in training as soon as possible. If a 
horse does not respond to other treatments, MPA could be an alternative if the owner 
understands that the horse needs a long time of rehabilitation after treatment. MPA could also 
be an alternative for hacking horses, which are not exposed for exercise in the same incidence 
as athletic horses. 
Based on this literature review corticosteroids can be a good alternative to treat OA if they are 
used correctly. So, what is meant by correct use of corticosteroids? First it is important to find 
the joint in which OA is developing in an early stage. TA can protect chondrocytes from stress 
so if a joint get an injection soon after the disease starts it can restore the balance between 
catabolic and anabolic processes. Good diagnostic is also an important thing. It is of great 
importance that the veterinarian only injects inflamed joints since it has been shown that 
corticosteroids affect the articular cartilage in different ways depending on the health status of 
the joint. It is of great concern that the horse is subject to strict rest after treatment and that the 
veterinarian has in mind that the horse may show up clinically healthy a few days after the 
injection because of the strong anti-inflammatory effects of corticosteroids. The cartilage still 
needs time to advert to normal function again and therefore, rest and time is essential for good 
long-term results of treatment.  
One difficult thing with corticosteroids is that you cannot accurately know how long they affect 
the joint. It is possible to see when it is undetectable in synovial fluid but that does not 
automatically means that the effect is gone since corticosteroids affect the genome and because 
of that can exert a longer effect. More pharmacokinetic and pharmacodynamics studies about 
corticosteroids are required. The fact that it is unknown how long corticosteroids affect the joint 
makes it difficult to know for how long the horse need to be out of training after intra-articular 
treatment with corticosteroids.  
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Even if there are a lot of questions left about corticosteroids, it is important to remember that 
we today do not have better options for treatment of OA. The discussion about corticosteroids 
negative effects on the articular cartilage makes many horse owners scared and reluctant to treat 
their horses intra-articular with corticosteroids. It cannot be excluded that corticosteroids do not 
affect the articular cartilage in an adverse way but it is absolutely certain that the cartilage will 
get damage if the inflammation in joint is not inhibited.  
In conclusion, there are no strong indications that articular cartilage becomes damaged after 
treatment with corticosteroids as long as the dosage is correct and the horse rest while the drug 
is acting. Further studies are required to get a better understanding of the use of corticosteroids, 
and comparative studies between different types of corticosteroids are desirable. Meanwhile, 
there is no reason to change the general view that corticosteroids are a good alternative for 
treatment of OA in horses.  
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